Federal Register / Vol. 75, No. 247 / Monday, December 27, 2010 / Notices 81283 

or before January 10, 2011. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

January 11, 2011. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact AnnMarie 

Williams, Conference Management 

Staff, 301–796–5966, at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: December 20, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–32367 Filed 12–23–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Oncologic Drugs Advisory Committee; 

Cancellation 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The meeting of the Oncologic 

Drugs Advisory Committee scheduled 

for February 9, 2011, is cancelled. This 

meeting was announced in the Federal 

Register of December 6, 2010 (75 FR 

75680). On February 9, 2011, the 

Oncologic Drugs Advisory Committee 

was scheduled to discuss biologics 

license application (BLA) 125377, with 

the proposed trade name YERVOY 

(ipilimumab), submitted by BristolMyers Squibb Co. The proposed 

indication (use) for this product is for 

the treatment of advanced melanoma in 

patients who have received prior 

therapy. This meeting has been 

cancelled because the issues for which 

FDA was seeking the scientific input of 

the committee have been resolved. 

FOR FURTHER INFORMATION CONTACT: 

Nicole Vesely, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, e-mail: 

Nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), and follow the 

prompts to the desired center or product 

area. Please call the Information Line for 

up-to-date information on this meeting. 

Dated: December 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–32413 Filed 12–23–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Child Health and 

Human Development Council. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Child Health and Human Development 

Council. 

Date: January 20, 2011. 

Open: 8 a.m. to 12:20 p.m. 

Agenda: (1) A report of the Director, 

NICHD; (2) Select Pay Plan Presentation; (3) 

NIH Peer Review Enhancement Update, (4) 

NIH Support for Human Embryonic Stem 

Cell Research Update. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C–Wing, 

Conference Room 6, Bethesda, MD 20892. 

Closed: 12:20 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C–Wing, 

Conference Room 6, Bethesda, MD 20892. 

Contact Person: Yvonne T. Maddox, PhD, 

Deputy Director, National Institute of Child 

Health and Human Development, NIH, 9000 

Rockville Pike MSC 7510, Building 31, Room 

2A03, Bethesda, MD 20892. (301) 496–1848. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxis, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nichd.nih.gov/about/nachhd.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

In order to facilitate public attendance at 

the open session of Council, reserve seating 

will be made available to the first five 

individuals reserving seats in the main 

meeting room, Conference Room 6. Please 

contact Ms. Lisa Kaeser, Program and Public 

Liaison Office, NICHD, at 301–496–0536 to 

make your reservation. Additional seating 

will be available in the meeting overflow 

rooms, Conference Rooms 7 and 8. 

Individuals will also be able to view the 

meeting via NIH Videocast. Please go to the 

following link for Videocast access 

instructions at: http:// 

wwwauthor.nichd.nih.gov/about/overview/

advisory/nachhd/virtual-meeting201005.cfm. The meeting is partially closed 

to the public. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 


erowe on DSK5CLS3C1PROD with NOTICES